<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541564</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-048</org_study_id>
    <nct_id>NCT03541564</nct_id>
  </id_info>
  <brief_title>An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects</brief_title>
  <official_title>A Randomized, Double-Blind, Positive-Controlled, Placebo-Controlled, 4-Period Crossover Study to Investigate the Electrocardiographic Effects of BMS-986165 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the experimental medication BMS-986165 in healthy participants
      in order to study the effects it has on electrocardiogram results.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Actual">September 4, 2018</completion_date>
  <primary_completion_date type="Actual">September 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected change from baseline in (Fridericia) QT Interval (QTcF) for BMS-986165 as determined by 12-lead electrocardiogram (ECG)</measure>
    <time_frame>From baseline to 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change from baseline in corrected (Fridericia) QT Interval (QTcF) for moxifloxacin as determined by 12-lead ECG</measure>
    <time_frame>From baseline to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (HR) as determined by 12-lead ECG</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QRS as determined by 12-lead ECG</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR as determined by 12-lead ECG</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in corrected (Fridericia) QT Interval (QTcF) as determined by 12-lead ECG</measure>
    <time_frame>From baseline to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of participant abnormalities in vital signs, clinical laboratory tests, safety 12-lead ECGs, and physical examinations</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AE)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAE)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) as determined by plasma concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) as determined by plasma concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] as determined by plasma concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] as determined by plasma concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>BMS-986165 Dose 1 oral administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986165 therapeutic single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986165 Dose 2 oral administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986165 supratherapeutic single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin Dose 3 oral administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin positive control single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dose 4 oral administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-986165 Dose 1 oral administration</arm_group_label>
    <arm_group_label>BMS-986165 Dose 2 oral administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Moxifloxacin Dose 3 oral administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Placebo Dose 4 oral administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy as determined by no clinically significant deviation from normal in medical
             history, physical examination, ECGs, and clinical laboratory determinations in the
             opinion of the investigator

          -  Body mass index of 18.0 to 32.0 kg/m2, inclusive, and body weight â‰¥ 50 kg, at
             screening

          -  Normal renal function at screening as evidenced by an estimated glomerular filtration
             rate (GFR) &gt; 80 mL/min/1.732 m2

        Exclusion Criteria:

          -  Any medical condition that presents a potential risk and/or may compromise the
             objectives of the study, including a history or presence of active liver disease

          -  A personal history of clinically relevant cardiac disease as determined by the
             investigator, symptomatic or asymptomatic arrhythmias, presyncope or syncopal
             episodes, or additional risk factors for torsades de pointes (eg, heart failure)

          -  History of hypokalemia, personal history or family history of prolonged QT interval,
             or family history of sudden cardiac death at a young age

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

